August 17, 2020
Authored and Edited by Adriana L. Burgy; Jill K. MacAlpine, Ph.D.; Michele C. Bosch; Thomas L. Irving; Stacy Lewis*, Melanie Magdun*
Almost seventy years ago, Congress passed the 1952 Patent Act, which included 35 U.S.C. §112(6), the first statutory language describing means-plus-function (“MPF”) claims. MPF claims define an element, in a combination claim, by its function instead of its structure. This statutory provision remains in action since then, though rebranded as §112(f) in the Leahy-Smith America Invents Act, 125 Stat. 284 (“AIA”). Despite the rebranding, the statutory language still reads:
35 U.S.C. §112(f) ELEMENT IN CLAIM FOR A COMBINATION.—An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof..
MPF claims, often thought of as very narrow, can in fact provide greater protection for patent applicants than can other types of claims, including for claims drawn to pharmaceutical subject matter. That is because the statutory term “equivalents” does not reference the doctrine of equivalents, but rather refers to literal equivalents of structure, material, or acts that perform the same function. By encompassing literal equivalents, an inventor’s claims can better protect an inventor’s rights. It can also better prevent competitors from drafting around the literal scope compared to claims that recite particular elements, as MPF claims will encompass alternatives that provide the same function as claimed.
In some circumstances, MPF claims describe the invention in a clearer, more precise, and even broader way than purely structural claims. Specifically, the functional part in the §112(f) combination covers the “corresponding structure, material, or acts described in the specification and equivalents thereof.” MPF claims are underutilized in pharmaceutical patents, but there are some that have sallied forth and have issued.
In Ex parte Gleave, Appeal 2012-004973 (P.T.A.B. Jan. 22, 2014), the PTAB reversed an examiner’s rejection and allowed a pharmaceutical claim using MPF language.[1] Applicants amended claim 33 to read:
33. (currently amended) A pharmaceutical composition comprising a
(a) means for reducing the amount of active hsp27 in cancerous cells [by sequence specific interaction with Seq. ID No. 91] and
(b) a pharmaceutically acceptable carrier.
This claim was rejected on several grounds, including §112(f). With respect to the MPF language, the examiner explained:
the instant specification does not describe any means for reducing the amount of active hsp 27 via sequence specific interaction other than by antisense oligonucleotide or RNAi inhibition. Therefore, the claims are broader than the instant disclosure, as this is not a defined genus that has been described by the specification. The specification does not have a sufficient disclosure of the structure that corresponds to the claimed function. Means plus-function claims require disclosure in the specification even if the means are already well known in the art.
On appeal, the PTAB agreed with Applicants that the MPF limitation was proper:
We agree with Appellants that the structures disclosed in the Specification as having the function recited in the claims are limited to (a) the specific antisense oligonucleotides in Example 1, (b) the specific RNAi molecules of Example 5, and (c) equivalents thereof, that are effective in reducing the amount of hsp27 in cancerous cells.
Appeal 2012-004973 at *7. As will readily be comprehended, such a claim could be particularly effective against a 505(b)(2) challenger[2] or a competitive innovator.
Another instance of pharmaceutical MPF claims surviving scrutiny can be found in U.S. Patent No. 10,413,611 (“the ‘611 Patent”), which claimed, in a combination: “(b) means for keeping the pharmaceutical composition in liquid phase up to a temperature of about 40° C in vitro.”
During prosecution, the examiner rejected this claim, explaining that it
fails to recite a combination of elements as required by that statutory provision and thus cannot rely on the specification to provide the structure, material or acts to support the claimed function. As such, the claim recites a function that has no limits and covers every conceivable means for achieving the stated function, while the specification discloses at most only those means known to the inventor. Accordingly, the disclosure is not commensurate with the scope of the claim.
The examiner was persuaded by Applicant’s response that “claim 1 recites a poloxamer and a means for, meaning it is not a single means claim because it does recite a combination of elements (a poloxamer in combination with means for).” The examiner allowed the claim which issued as independent claim 1 in the ‘611 patent. Such a claim could be very useful against an ANDA challenger[3] who copies the active ingredient but tries to pirate the invention by changing the formulation.
Further examples of issued pharmaceutical MPF claims include:
Takeaway: Overall, MPF language can be a powerful tool in drafting pharmaceutical claims to encompass broader claim scope and thus more fully protect an inventor’s rights and provide greater protection against infringement. While there have been relatively few pharmaceutical patents utilizing this language, some MPF pharmaceutical claims, as seen herein, are being issued by the USPTO.
[1] For a more detailed analysis of this decision, see Irving and Lewis, An Issued Life Science MPF U.S. Patent Claim: Ex parte Gleave, Finnegan Prosecution First Blog,https://www.finnegan.com/en/insights/blogs/prosecution-first/an-issued-life-science-mpf-u.s.-patent-claim-ex-parte-gleave.html
[2] Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 355(b)(2): An application submitted under paragraph (1) for a drug for which the investigations described in clause (A) of such paragraph and relied upon by the applicant for approval of the application were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted ...
[3] Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j) Abbreviated new drug applications
(I) that such patent information has not been filed,
(II) that such patent has expired,
(III) of the date on which such patent will expire, or
(IV) that such patent is invalid or will not be infringed by the manufacture, use, or sale of the new drug for which the application is submitted; and…
patent application drafting, means-plus-function claim, pharma patent strategy, functional claiming, specification
*Stacy Lewis is a Law Clerk at Finnegan.
*Melanie Magdun is a Summer Associate at Finnegan.
Copyright © 2020 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
INCONTESTABLE® Blog
April 19, 2024
Federal Circuit IP Blog
March 21, 2024
Conference
2nd Annual Forum on IP, Funding and Tech Strategies for Novel Therapeutic Modalities
March 20, 2024
Boston
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.